# GEO for healthcare, legal and financial businesses

> In health, money and law, an inaccurate AI answer can hurt people, and an over-promising page can break advertising law. Put compliance review first, publish verifiable facts with named experts and dates, keep content balanced, and keep it current. Promotional content that dodges ad review is the main legal risk.

- URL: https://geo.casa/best-practices/regulated-industries/
- Guide · Officially documented
- Reviewed: 2026-10-28

This guide is for marketing, content and compliance teams in healthcare, pharma, law, finance, insurance and education. In these fields, AI answers can affect someone's health or money. It covers how to be cited accurately without breaking advertising rules. Expect the compliance review cycle, not the writing, to set your pace.

## The short version

1. Bring legal and compliance in before any content is planned, and agree the red lines.
2. Publish verifiable facts with named, qualified authors and review dates.
3. Keep claims balanced: benefits with risks, limits and who something is not for.
4. Treat any content that promotes a product as advertising, with the review and labels that requires.
5. Keep facts current, because AI repeats outdated information for a long time.
6. Monitor what assistants say about you and correct errors through your own sources.

## 1. Compliance first

In regulated fields, a page that gets cited and is wrong does more harm than a page nobody cites. Reviewing after publication is too late, because AI may already have picked the content up.

> **Observed in practice:**
> Analysys's GEO practice report for the financial sector recommends bringing legal and compliance teams in at the first, diagnostic stage. They agree content red lines and the review process before any content work starts. The report also recommends regular checks on whether content cited by AI is outdated or non-compliant. (Translated from Chinese; the report describes practice and gives no measured data.)
>
> Sources: 易观分析: 2026中国GEO行业场景实践报告——金融行业 (unpublished report, not publicly available; readers can't check it)

> **Observed in practice:**
> IQVIA and a partner describe pharma content as passing four review layers, against two for consumer goods. The two extra layers are medical accuracy and balance of information. Medical, legal and compliance sign-off typically takes 5–10 working days per article, and a piece takes two to three weeks or more from start to publication. (Translated from Chinese.)
>
> Sources: 艾昆纬（IQVIA）· 上海零假设信息科技: 穿透医药GEO：医药品牌的内容可见性重构 (unpublished report, not publicly available; readers can't check it)

Plan for this. Agree a short, standing list of approved facts (indications, rates, fees, qualifications) that writers can use without a new review each time.

## 2. Show who stands behind the content

Google holds health, finance and safety topics to a higher standard. Other assistants do not document comparable rules, but they cite pages they can trust and verify.

> **Officially documented:**
> Google's systems give "even more weight to content that aligns with strong E-E-A-T" on Your Money or Your Life (YMYL) topics. These are topics that could significantly affect people's health, financial stability or safety, or the welfare of society.
>
> Sources: [Google Search Central: Creating helpful, reliable, people-first content](https://developers.google.com/search/docs/fundamentals/creating-helpful-content)

> **Officially documented:**
> "While E-E-A-T itself isn't a specific ranking factor, using a mix of factors that can identify content with good E-E-A-T is useful." Of its aspects, trust matters most.
>
> Sources: [Google Search Central: Creating helpful, reliable, people-first content](https://developers.google.com/search/docs/fundamentals/creating-helpful-content)

So there is no badge or markup that makes a page trustworthy. What helps readers and systems judge it:

- the author's name, qualification and licence number where the profession has one;
- a named medical, legal or financial reviewer and the date of review;
- citations to guidelines, statutes, approved labels or regulator filings;
- clear ownership: who runs the site and how to contact them.

Background: [E-E-A-T](https://geo.casa/foundations/e-e-a-t/) and [People-first content](https://geo.casa/foundations/people-first-content/).

## 3. Keep claims balanced

Promotional, one-sided content is both a legal risk and a poor source for an assistant.

> **Observed in practice:**
> The IQVIA authors report that Chinese AI platforms such as Doubao and DeepSeek assess the balance of content on prevention, diagnosis and treatment. When content describes a drug's advantages one-sidedly, the AI often adds competitor information or risk warnings when it cites it. (Translated from Chinese; the report does not say how this was measured.)
>
> Sources: 艾昆纬（IQVIA）· 上海零假设信息科技: 穿透医药GEO：医药品牌的内容可见性重构 (unpublished report, not publicly available; readers can't check it)

Write the way a careful professional would explain it to a client:

- state who a treatment, product or service is for, and who it is not for;
- give risks, side effects, fees and conditions next to the benefits;
- avoid absolute words ("best", "guaranteed", "cure", "risk-free").

## 4. Promotion is advertising, wherever it appears

China's advertising rules apply to promotional content whether it looks like an ad or like an article. GEO content that promotes a product falls under them.

> **Officially documented:**
> China's Advertising Law bans superlatives such as national-level, highest or best in ads (Article 9). Medical, drug and medical-device ads must not claim guaranteed efficacy or safety or cite cure or effectiveness rates (Article 16). They, and other ads requiring review, must pass review by the authorities before publication (Article 46).
>
> Sources: [国家市场监督管理总局: 中华人民共和国广告法](https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_5474cf75173c45d6a0379730fb4e8d97.html)

> **Officially documented:**
> Education and training ads must not promise admission, passing exams, degrees or results (Article 24). Ads for investment products with expected returns must carry reasonable risk warnings and must not promise returns or imply guaranteed profit (Article 25).
>
> Sources: [国家市场监督管理总局: 中华人民共和国广告法](https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_5474cf75173c45d6a0379730fb4e8d97.html)

> **Officially documented:**
> China's Internet Advertising Measures (in force since 1 May 2023) ban online prescription drug ads (Article 6). Article 8 bans disguised ads for medical services, drugs, medical devices and health foods presented as health or wellness knowledge. Such content must not show the provider's address, contact details or purchase link on the same page.
>
> Sources: [中国政府网（国务院公报 2023年第16号）: 国家市场监督管理总局令（第72号）　　互联网广告管理办法](https://www.gov.cn/gongbao/2023/issue_10506/202306/content_6885261.html)

> **Officially documented:**
> Article 9 requires online ads to be identifiable as ads. Content that sells through knowledge sharing, experience posts or product reviews, with a purchase link attached, must be clearly labelled as an ad.
>
> Sources: [中国政府网（国务院公报 2023年第16号）: 国家市场监督管理总局令（第72号）　　互联网广告管理办法](https://www.gov.cn/gongbao/2023/issue_10506/202306/content_6885261.html)

In practice, separate educational content from promotion. A disease explainer that ends with your clinic's booking link is the pattern Article 8 targets.

> **Observed in practice:**
> A 2026 education-sector GEO white paper sets out a "negative list" for content review, based on the Advertising Law and rules on minors and off-campus training. It bans absolute terms, promises such as "guaranteed pass" or "guaranteed job", and invented pass or employment rates. It also bans training ads without a licence and invented teacher credentials or official partnerships. (Translated from Chinese.)
>
> Sources: 校长邦 · 教育宝: 2026教育行业GEO白皮书 V1.0 (unpublished report, not publicly available; readers can't check it)

Outside China, check your own regulator's rules on health, legal and financial promotion. The US rule on fake reviews applies across industries:

> **Officially documented:**
> It is a violation "for a business to write, create, or sell a consumer review, consumer testimonial, or celebrity testimonial that materially misrepresents, expressly or by implication" that the reviewer exists or used the product, or their experience with it.
>
> Sources: [US Federal Trade Commission (eCFR): 16 CFR Part 465 -- Use of Consumer Reviews and Testimonials](https://www.ecfr.gov/current/title-16/chapter-I/subchapter-D/part-465)

> In health, money and law, being cited wrongly is worse than not being cited at all. Compliance is the price of being quoted.

## 5. Keep facts current

AI models and their sources lag behind your approvals, filings and rate changes.

> **Observed in practice:**
> In a case the IQVIA authors describe, a cancer drug gained a new first-line indication. DeepSeek still left it out of answers about first-line treatments. Asked about the drug's indications, the AI did not mention the new one and cited subgroup data from two years earlier. (Translated from Chinese.)
>
> Sources: 艾昆纬（IQVIA）· 上海零假设信息科技: 穿透医药GEO：医药品牌的内容可见性重构 (unpublished report, not publicly available; readers can't check it)

- Update your own pages on the day an approval, rate or fee changes, and show the date.
- Retire or redirect old pages rather than leaving contradictory versions online.
- Label AI-generated content you publish in China, as required since September 2025:

> **Officially documented:**
> In force since 1 September 2025. AI-generated content carries explicit labels people can see, and implicit labels in file metadata. Users who publish AI-generated content must declare it.
>
> Sources: [国家互联网信息办公室: 关于印发《人工智能生成合成内容标识办法》的通知](https://www.cac.gov.cn/2025-03/14/c_1743654684782215.htm)

## What not to do

- **Don't seed "independent" recommendations or rankings.** Google's spam policies cover this, and so does China's 2026 Qinglang campaign ([GEO regulation in China](https://geo.casa/foundations/geo-regulation-china/)).

> **Officially documented:**
> Google's definition of spam includes "attempting to manipulate generative AI responses in Google Search."
>
> Sources: [Google Search Central: Spam policies for Google web search](https://developers.google.com/search/docs/essentials/spam-policies)

- **Don't use health "knowledge" articles as disguised ads** (Article 8 above).
- **Don't publish outcome guarantees,** such as cure rates, pass rates or guaranteed returns.
- **Don't let a vendor publish without your approval.** Write a review step into the contract ([Before you hire a GEO agency](https://geo.casa/best-practices/choose-agency/)).
- **Don't invent credentials, awards or expert endorsements.**

> If a sentence couldn't go in your printed ad, it shouldn't go in an article written for AI.

## How you'll know it's working

Accuracy comes first here. Count both whether assistants mention you and whether what they say is correct and current.

1. List the questions patients, clients or investors ask, including ones about risks and costs.
2. Sample answers repeatedly in the assistants they use ([Measuring AI visibility by sampling prompts](https://geo.casa/measurement/ai-visibility-measurement/)).
3. Score each answer for mention, factual accuracy, currency and balance.
4. Log errors and trace each one to a source you can correct ([When AI gets your brand wrong: find it, fix it, prevent it](https://geo.casa/best-practices/wrong-ai-answers/)).
5. Report accuracy rates alongside visibility to compliance as well as marketing ([For marketing leads: measuring GEO and reporting it upward](https://geo.casa/best-practices/measure-report/)).

## Evidence at a glance

| Recommendation | Evidence |
|---|---|
| Compliance review before content | Observed (industry practice reports) |
| Named experts, sources, review dates | Official (Google, for YMYL); benefit for other assistants not documented |
| Balanced claims | Official (advertising law); observed (pharma report) |
| Treat promotion as advertising, label it | Official (Chinese Advertising Law, Internet Advertising Measures) |
| Keep facts current | Observed (pharma case) |
| Label AI-generated content in China | Official (CAC) |
| No seeded recommendations or fake reviews | Official (Google, FTC, CAC) |

## Sources

- [Google Search Central: Creating helpful, reliable, people-first content](https://developers.google.com/search/docs/fundamentals/creating-helpful-content)
- [Google Search Central: Spam policies for Google web search](https://developers.google.com/search/docs/essentials/spam-policies)
- [国家市场监督管理总局: 中华人民共和国广告法](https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_5474cf75173c45d6a0379730fb4e8d97.html)
- [中国政府网（国务院公报 2023年第16号）: 国家市场监督管理总局令（第72号）　　互联网广告管理办法](https://www.gov.cn/gongbao/2023/issue_10506/202306/content_6885261.html)
- [国家互联网信息办公室: 关于印发《人工智能生成合成内容标识办法》的通知](https://www.cac.gov.cn/2025-03/14/c_1743654684782215.htm)
- [US Federal Trade Commission (eCFR): 16 CFR Part 465 -- Use of Consumer Reviews and Testimonials](https://www.ecfr.gov/current/title-16/chapter-I/subchapter-D/part-465)
- 艾昆纬（IQVIA）· 上海零假设信息科技: 穿透医药GEO：医药品牌的内容可见性重构 (unpublished report, not publicly available; readers can't check it)
- 易观分析: 2026中国GEO行业场景实践报告——金融行业 (unpublished report, not publicly available; readers can't check it)
- 校长邦 · 教育宝: 2026教育行业GEO白皮书 V1.0 (unpublished report, not publicly available; readers can't check it)